Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If your content with the evaporation of your entire account please put me on ignore. If this were a checking account maybe you would be more concerned. Even hacking of a social media account can cause problems depending on what they post. Asking everyone to believe that an arbitrary closing of an account and reopening of a new one on your name (as in email address and ihub password) is ‘normal’ and ok is crazy for you and anyone who believes you.
A normal person would be upset.
I’m leaning toward lying as it’s a new account not a renamed user
You should change your password to ihub. That is if what you say happened did. It doesn’t seem likely though someone would be ok with their entire posting history being wiped out. So I lean toward you being someone who just joined and is trying to leverage someone else’s reputation for their own purpose.
If that isn’t the case you should contact support. Your account name didn’t change your a new account
Whether it goes down significantly again, in my opinion, depends on how much of an impact to the schedule these FDA mtgs will ultimately have. Many here have decided it will be weeks, but if it’s 2 or 3 months that will affect price. Two or three months when we have been waiting years could legitimately be considered not a big impact by Korenko, but I think investors will feel differently.
Name them.
What news is expected next week? We are about a month from any news as far as info related in last CC. Keep it honest here. It’s so good we don’t need to fudge. Just be patient.
It basically says don’t prescribe high doses…..which is true of most every prescription drug. Not an issue and isn’t going to stop anyone from prescribing or taking adderall.
In very rare cases 2 aspirin can kill some people. Not much on this planet that doesn’t cause harm to someone. Think about peanuts and how many kids they kill, yet we can still buy peanut butter without a prescription
You must be joking.
Show some numbers to justify that value.
Think about it. We have $70 million in revenue with current product market. A share price of $0.4 and a P/E of 20ish. Our potential revenue will at least double with approved products alone . This means once we start making those sales assiming a P/E of 20 share price will be about $0.8 That is with all approved products on market having market value of about $2 billion
Now add in Vyvanse launch. If we get 10% of a $3billion market that should push share price to at least $1.2 assume conservative PE of 10. But I don’t think the P/E will be 10 because we know we have more billion dollar products in the pipeline e. Nudge the P/E to 15 and you have the $1.80. If it stays at the current 20 we are in the $2 range
This is the math explaining what is happening. I don’t think we going to get another article because the people who would write it are buying. The won’t promote it until price reflects market value. I think our holding sound 40 with maybe a pop to 50 cents before coming back down to 40 cents is reasonable. But when we get Vyvanse approval in Nov, stand back for the second stage burners engaging. If we also get the BE results for the third needle mover CNS there will be yet another move up.
Frankly it’s a bit overwhelming to think about.
The market is forwarding looking. The Aug call made it crystal clear that the next 6 months would be transformative for the company. It wasn’t a ‘it might be’ major uptick in revenue it was it will be. That will happen independent of the large CNS product that is expected to be approved in Nov.
Add that likely event (because FDA already told the company they have no majors concerns with their submission), and you get revenue growing by more than 3 times in the next 6 months.
The market couldn’t ignore our reality. Longs had plenty of time to invest heavily after the call. I hope everyone who could did.
You are looking at P/E of drug companies that bring new drugs to market. These drugs have a huge mark up to pay for the cost of getting them to market. You have to limit your search to generic drug companies.
Buyout or merger/acquisition is what Nasrat says. So a big company can buy all outstanding shares or a smaller company buys a portion of us or we buy a portion of a smaller company. I believe Nasrat will decide based on what he and the board is best for shareholders.
The first run was all about SequestOx. At the time many believed abuse deterrent opioids may become the only opioids prescribed. The valuation was based on that one patented abuse deterrent product. We had a submission to FDA that got a CRL, but before that price spiked. Nasrat was also considering getting into a partnership with a deep pocket money as part of bringing that drug to market. That possibility kept me invested longer than I would have otherwise. Then the CRL, some talking from Nas about trying to address the problem of the drug needing to be taken with food for it to be truly BE (as price plummetted). Then a few months after that Nas saved our bums by striking up by the deal with Sun (I think that was pharma’s name) to co-develop Adderall together.
News of methotrexate is going to drop any day now. No doubt about that.
Changing one’s mind after being proven wrong is called being wrong.
Concerta BE results could happen before end of year. This tidbit from Carter in the CC hasn’t been emphasized much. Given we know from previous CCs the next product up is another needle mover. Sounds like the development of that is on schedule. Nasrat did say in an earlier CC positive BE results this calendar year was a possibility.
No, what everyone is doing is wishing you had stayed away for as long as you promised. I have to admit on rare occasion you used to post something useful. No more, though…..it seems you lost your ‘game’.
Those buying now are buying for the run over six months. Ability to drive this is down is drying up as are shares at this price. Elite is not diluting. We know we have a PR hitting in a week or so. Even daytraders are gonna be interested in the current price.
I wasn’t referring to your posts. We have a sticky saying Nazareth is going to jail for chrissakes. That should not be a sticky. The fact that it speaks volumes about who manages this board.
There is a big difference between ‘disagreeing with some actions’ and calling for a man to go to jail and removed as CEO. Nasrat is responsible for us being in the excellent financial position we are currently in. If he were to disappear overnight, stock value would crash.
Hence people calling for his head are at best dumb and bad for stock price at worst trying to mislead investors.
Nasrat is old and has been wanting to build up the company ASAP to sell it. He could have died during the wait for drugs to be developed and the opioid lawsuit risk diminish. This would have left his family hanging with lots of stock in an unproven company. He had no clue he would be able to buy the products back. So your conspiracy theory of a master plan has no legs. Not taking profit of opioids when the lawsuits were raging was equaling damaging and protective to Nasrat, the board and shareholders alike. Your back on ignore because reading your posts is like a listening to a broken record.
Showing I am very bullish by doing it again
Not sure how the bearish sign hit on my post I usually don’t add that so correcting it here
So many words to say basically my theory about why you are so negative about the company, no matter the performance, was right but the motivation I attributed was wrong. Clearly stating that you don’t believe Nasrat and the board did it to decrease risk of litigation from opioid llawsuits. Then you turn around and tell a long winded story about how it could have been because of risk. Ending it all by asking me whose risk was mitigated like there is some smoking gun that anyone here cares about.
What a dumb question to ask at all much less years after the fact and when the company has the key products back at same price.
BTW, the risk doesn’t have to be from legitimate lawsuits that would win. A company has to defend itself from ALL lawsuits. Ask the great granddaughter of Elvis Presley how much she spent in court fighting a completely made up foreclosure claim on Graceland.
States and cities were filing class action lawsuits. One could easily have been against every single company that manufactured opioids by lawyers to cast a wide net and get as much as they could.
With your profession I would have thought you would know that lots of lawsuits are filed that never have a chance of winning. But apparently you are a rare doctor that has never faced a malpractice suit or you have only faced lawsuits with legitimate claims that you were guilty of?
The perception hasn’t hurt us. Owning Adderall would barely move our share price. And, of course, it’s always about the money. To state otherwise is you admitting you have no credibility.
He got pissed when Nasrat sold the opioids. He thought it was an over reaction to the risk and I think he had invested a good bit in expectation of them going to market. Price tanked and I’m pretty sure he stopped buying. Even selling some to buy the infamous used Volvo. The Milah deal doesn’t matter. The amount the Adderall income has given Milah is around 4 milllion since the deal went through. Peanuts!
He can’t complain about the opioids now because we bought them back about as cheap as we sold them. Now the problem is he didn’t buy more shares when it was cheap for months and months and missed out. He could buy, now as it is another great time, but he can’t do it. Too bitter about it not doing what he expected the last time.
Price moved up over 500% in the last year. If you aren’t happy with that you didn’t buy enough shares in the 4 cent range. You had about a year to do that. Seems like the whiners are still whining because they missed out.
Besides we don’t need a buyback to move up we need new product launches. And that is exactly what Nasrat is going to give us starting in about a week and continuing every 7ish weeks for six months. So for the love of god buy now and stop whining. There is almost no risk to buying now. You won’t make out like you would have if you bought at 4 cents but better late than never.
CEO can continue to the Mikah crap. It didn’t stop the run from 3 to 20 cents and won’t stop our upcoming run. It’s an issue only in a few poster minds. I don’t know how they don’t feel impotent given how little the market cares about their Mikahgate nonsense.
The Dopamine Agonist wasn't mentioned in the CC in context of the launches. He noted it was under review but not included in the first 5 products to be launched. Sixth will be Vyvanse, so maybe 7th, but that pushes it out all the way to early summer next year. I'm sure we will have a more valuable drug to launch by then. Its only $12M in revenue. If they ever get a window to launch it they probably, will be most of us here hope they stay busy with other product. Leaving it off is only an issue for people who are think a purpose in life is to find small errors in public message board posts.
It will be interesting to see when the market wakes up to Elite's upcoming revenue flow. All the data is out there is the market putting it together and building its future cost into the current price. I'm not sure Methotrexate will do it, it might take a second drug. Obviously once we get to Percocet at $500M our price will have improved. That lets us get some capital gains at this years tax rate. Plan for it!
To see if you would come crawling back to board after you said you would leave for 6 months…you fell for it
Isopet posted a pic from vegas. Good to see they are still out there trying to drum up business. Hopefully at the end of their travels we have a few more clinics. We need to move up from 1 or 2 treatments a quarter. If six clinics only see that many pets that need the procedure that we will need a bunch of them to turn a meaningful profit. Although the idea of less pets with cancer needing treatment is a happy thought.
Next June Elite will likely be reporting at least $70M in revenue per quarter.
This is a conservative estimate based on the launches of the approved drugs and Vyvanse.
Lets break them down.
1. Methotrexate $64.3M
Launching between Aug 19 and Sept 2
2. Tylenol with Codeine $43M
Launching between October 7 and October 21
3. Percocet $500M
Launching between Nov 18 and Dec 30
4. Norco $477M
Launching between Dec 30 and Jan 13
5. Methadone 30M
Launching between Jan 13 and end of February 3
Just 5% of all revenue is $55 million or $14M per quarter. Five percent is a very conservative estimate. What this says is in six months we will have almost doubled our revenue.
6. Now toss in Vyvanse. $3B
If we assume a conservative 5% of a 3 billion market that would, at a minimum raise or income by another $38M per quarter.
Launch will be 2 to 3 months after it is approved.
Making our revenue stream 38+14+18 = 70M, wow!
Agree completely. He went to re-hashing a bunch of stuff that has been discussed at length. Pretty much revealed himself, yet again, to be someone that wants attention and not an actual investor. I took him off ignore late Friday and he was back on early this morning. Ignore is a beautiful feature!
Seems like the IsoPet Van tour has stopped posting since a bit after the IDE delay. I wonder if they got called back until the IDE issue is resolved. Short-term cash reserves is an issue until we know what FDA wants. We really need the cash on hand to meet whatever needs they have as dilution would not be great right now. My guess is they have a private placement lined up to go through after the IDE approval.
We are almost half way through the 45 day window that Korenko estimated it would take to submit new IDE. From Korenko's post Friday it sounds like they have just recently sent off a response to at least one of the FDAs questions. With the BBD designation I think we should hear back from FDA in about a week. If that issue was addressed, and it was the only issue we would probably be re-submitting IDE just as the 45 day window expires.
JamesF1, you, like winechemist, provided information to this board that investors wouldn't be able to find easily, if at all, without you. Thank you for providing your insight and sharing your thoughts on Elite. We are lucky to have you participating here.
We are very fortunate to have winechemist participating on this board. He confidence in the company, given his knowledge of the business should be a comfort to all longs that their belief in the company is supported by facts.
Very cool. I would like to know if the paper reached out to them or vice versa. Regardless its an awesome article. Fingers cross the FDA doesn't screw us over again.
The first question I asked ChatGPT and its answer
1. what is 'the sprint process' as it relates to FDA Breakthrough device program?
from ChatGPT:
If a device's sprint process involves dosimetry, it means that the issue or challenge being addressed relates to the measurement, calculation, or assessment of the dose of radiation absorbed by a person or an object, typically in the context of medical devices that use or measure radiation.
Specific Implications:
Radiation Safety: Dosimetry is critical in ensuring that medical devices that involve radiation (e.g., X-ray machines, radiation therapy devices, or imaging equipment) deliver the correct dose safely. The sprint process might focus on ensuring that the device accurately measures or controls radiation exposure to avoid under- or over-dosing.
Calibration and Validation: The sprint process might address the calibration, validation, or accuracy of the dosimetry function within the device. This could involve reviewing the methods used to calculate doses, verifying that the device delivers consistent and accurate measurements, and ensuring that it meets regulatory standards.
Regulatory Compliance: The sprint process may also focus on ensuring that the dosimetry aspects of the device comply with relevant FDA regulations and guidelines. This could include addressing any discrepancies or uncertainties related to dosimetry data or demonstrating that the device meets specific performance criteria.
Patient Safety: Ensuring proper dosimetry is vital for patient safety, particularly in devices used for radiation therapy, where the precise dose of radiation is critical for effective treatment while minimizing harm to surrounding tissues. The sprint process might aim to resolve any concerns about the accuracy or safety of the dosimetry features.
Development of New Dosimetry Technology: If the device involves innovative dosimetry technology, the sprint process might focus on validating this new approach, ensuring that it provides accurate and reliable measurements, and determining how it compares to existing standards.
In summary, if dosimetry is a focus of the sprint process, it indicates that the FDA and the device sponsor are working to resolve issues related to the measurement or control of radiation doses, with a strong emphasis on accuracy, safety, and regulatory compliance.